Novartis says Kesimpta gets EU approval in multiple sclerosis

Health News
FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company’s headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau

ZURICH (Reuters) – Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

The Swiss drugmaker is developing and marketing the product under a license agreement with Genmab.

Source: Read Full Article

Related posts:
  1. UK startup develops gyroscope glove to ease tremors for those with Parkinson's
  2. U.S. health body questions AstraZeneca's COVID-19 vaccine trial data
  3. Canada pauses AstraZeneca COVID-19 vaccine use for those under 55, wants new risk analysis
  4. Leaders in US, Europe divided on response to surging virus
  5. Eli Lilly's antibody combination receives FDA emergency use authorization for COVID-19